Conexeu Sciences Inc.
For the period ended Jul 7, 2026. Filed Jul 7, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Jul 7, 2026 · Filed Jul 7, 2026
Contents
EX-99.1 · Cautionary Statement
Cautionary Statement
CXU™ and the Company's device candidates, including Ten-Minute Tissue™, are investigational and have not been cleared or approved by the U.S. Food and Drug Administration or any other regulatory authority for any use. Nothing in this news release should be interpreted as a claim that any Conexeu product is safe or effective, is available for sale, or has received regulatory clearance or approval. The P.R.O.O.F study is a preclinical, animal-model study. Preclinical results are not necessarily predictive of results in humans, and the Company is not disclosing detailed findings, quantitative data, or individual study endpoints at this time. These are preclinical findings; they have not been peer-reviewed, and clinical significance has not been established.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.